0.00Open2.80Pre Close0 Volume5 Open Interest13.00Strike Price0.00Turnover120.57%IV2.02%PremiumJan 17, 2025Expiry Date2.59Intrinsic Value100Multiplier22DDays to Expiry0.21Extrinsic Value100Contract SizeAmericanOptions Type-0.7149Delta0.1101Gamma3.44Leverage Ratio-0.0230Theta-0.0053Rho-2.46Eff Leverage0.0088Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet